Aprea Therapeutics, Inc. Quarterly Debt-to-equity in % from Q2 2020 to Q2 2023

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Aprea Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q2 2020 to Q2 2023.
  • Aprea Therapeutics, Inc. Debt-to-equity for the quarter ending June 30, 2023 was 15.1 %, a 45.9% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2023 15.1 -12.8 -45.9% Jun 30, 2023
Q1 2023 44.5 +28.2 +173% Mar 31, 2023
Q4 2022 36 +19.6 +119% Dec 31, 2022
Q3 2022 30.7 +12.9 +72.8% Sep 30, 2022
Q2 2022 27.8 +10.6 +61.6% Jun 30, 2022
Q1 2022 16.3 -0.18 -1.1% Mar 31, 2022
Q4 2021 16.4 +1.75 +11.9% Dec 31, 2021
Q3 2021 17.8 +6.12 +52.6% Sep 30, 2021
Q2 2021 17.2 +0.07 +0.41% Jun 30, 2021
Q1 2021 16.4 Mar 31, 2021
Q4 2020 14.7 Dec 31, 2020
Q3 2020 11.6 Sep 30, 2020
Q2 2020 17.2 Jun 30, 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.